Welcome to our weekly briefing on R&D headlines that are shaping technology, healthcare, and industry. In this edition, we explore NVIDIA’s global expansion plans (plus a sharp rebuttal to new U.S. AI policy), Google’s ambitious Gemini user goals, a big-ticket pharma acquisition, tighter U.S. chip controls, and more. Keep reading for the latest developments and…
In 2024, the US and Europe led in pharma value creation while GLP-1s disrupted the landscape
GLP-1 juggernauts Eli Lilly and Novo Nordisk, whose combined $1.18 trillion market cap now exceeds Johnson & Johnson, AbbVie, and Merck combined, have staked their claim as stock market darlings. This momentum is particularly evident in Novo Nordisk’s remarkable trajectory, reaching a $604 billion market capitalization by March 2024 and securing its position as the…